Cancer Relapsed Refractory Multiple Myeloma clinical trials

Explore recruiting cancer relapsed refractory multiple myeloma clinical trials.

Recruiting cancer relapsed refractory multiple myeloma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cancer Relapsed Refractory Multiple Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM)

Greece, Czechia, Portugal

Therapeutic exploratory (Phase II) EU CTIS Study details

Cancer Relapsed Refractory Multiple Myeloma trials by city

Cancer Relapsed Refractory Multiple Myeloma clinical trials

Recruiting cancer relapsed refractory multiple myeloma studies right now

Elranatamab in Relapsed/Refractory Multiple Myeloma

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Plan Development for Giving Teclistamab in the Outpatient Setting

A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

Also recruiting in Europe

A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM)

Cancer Relapsed Refractory Multiple Myeloma trials by city

Other conditions